Cybin (NASDAQ:HELP) Releases Earnings Results

Cybin (NASDAQ:HELP) issued its quarterly earnings results on Monday. The company reported $999.00 EPS for the quarter, Zacks reports.

Cybin Stock Performance

Cybin stock opened at $6.88 on Tuesday. The firm has a market cap of $355.49 million, a P/E ratio of -1.63 and a beta of 0.74. The business’s 50-day simple moving average is $4.88. Cybin has a one year low of $3.76 and a one year high of $9.83.

Institutional Trading of Cybin

Several institutional investors and hedge funds have recently bought and sold shares of HELP. Osaic Holdings Inc. grew its stake in Cybin by 46.7% in the second quarter. Osaic Holdings Inc. now owns 7,543 shares of the company’s stock valued at $63,000 after purchasing an additional 2,400 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Cybin by 66.8% in the 2nd quarter. Bank of America Corp DE now owns 29,443 shares of the company’s stock valued at $247,000 after buying an additional 11,790 shares during the last quarter. Finally, Millennium Management LLC grew its stake in shares of Cybin by 1,388.5% in the fourth quarter. Millennium Management LLC now owns 1,028,549 shares of the company’s stock valued at $8,414,000 after buying an additional 959,448 shares in the last quarter. Institutional investors own 17.94% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on HELP shares. TD Cowen started coverage on Cybin in a report on Monday, April 13th. They set a “buy” rating for the company. HC Wainwright boosted their target price on Cybin from $55.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Five analysts have rated the stock with a Buy rating, According to MarketBeat, Cybin currently has an average rating of “Buy” and an average target price of $58.75.

About Cybin

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.